Weakness of urinary sphincter and pelvic floor muscles can cause insufficient urethral closure and lead to stress urinary incontinence (SUI). Bimagrumab is a novel myostatin inhibitor which blocks activin type II receptors, inducing skeletal muscle hypertrophy and attenuating muscle weakness.